


Healthcare News Roundup: Biopharmaceuticals
HSMN NewsFeed - 11 Mar 2021
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
HSMN NewsFeed - 9 Mar 2021
Lilly Announces Leadership Transitions in Manufacturing and Ethics and Compliance Organizations
Lilly Announces Leadership Transitions in Manufacturing and Ethics and Compliance Organizations
HSMN NewsFeed - 1 Mar 2021
Perrigo Announces Agreement To Sell Generic Rx Business For $1.55 Billion In Total Consideration
Perrigo Announces Agreement To Sell Generic Rx Business For $1.55 Billion In Total Consideration
HSMN NewsFeed - 24 Feb 2021
Clarus Therapeutics Appoints Richard 'Ric' Peterson as Chief Financial Officer
Clarus Therapeutics Appoints Richard 'Ric' Peterson as Chief Financial Officer
HSMN NewsFeed - 18 Feb 2021
OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development
OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development
HSMN NewsFeed - 15 Feb 2021
Avexegen Therapeutics Receives a $2.94M NIH Grant to Advance Treatment for Inflammatory Bowel Disease
Avexegen Therapeutics Receives a $2.94M NIH Grant to Advance Treatment for Inflammatory Bowel Disease
HSMN NewsFeed - 10 Feb 2021
AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products
AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products
HSMN NewsFeed - 9 Feb 2021
Lannett Expands Strategic Relationship To Include Biosimilar Fast-Acting Insulin
Lannett Expands Strategic Relationship To Include Biosimilar Fast-Acting Insulin
HSMN NewsFeed - 5 Feb 2021
Jubilant Therapeutics Appoints Dr. Robert Glassman to its Board of Directors
Jubilant Therapeutics Appoints Dr. Robert Glassman to its Board of Directors
HSMN NewsFeed - 2 Feb 2021
Actimed Therapeutics Appoints Frank Misselwitz MD, PhD as Chief Medical Officer
Actimed Therapeutics Appoints Frank Misselwitz MD, PhD as Chief Medical Officer
HSMN NewsFeed - 28 Jan 2021
Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate
Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate
HSMN NewsFeed - 19 Jan 2021
Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies
Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies
HSMN NewsFeed - 18 Jan 2021
Tessa Therapeutics Receives PRIME Designation from European Medicines Agency for CD30 CAR-T Therapy
Tessa Therapeutics Receives PRIME Designation from European Medicines Agency for CD30 CAR-T Therapy
HSMN NewsFeed - 15 Jan 2021
Lilly Announces $30 Million Limited Partner Investment in Unseen Capital Health Fund
Lilly Announces $30 Million Limited Partner Investment in Unseen Capital Health Fund
